Answers are grounded in this paper and cite their sources.
BACKGROUND AND OBJECTIVE: to describe the development or progression of subfoveal fibrosis after anti-vascular endothelial growth factor (VEGF) therapy in the absence of significant subfoveal hemorrhage in neovascular age-related macular degeneration. PATIENTS AND METHODS: retrospective case series. RESULTS: seven eyes of seven patients with neovascular age-related macular degeneration developed subfoveal fibrosis after anti-VEGF therapy in the absence of significant subfoveal hemorrhage. Five of seven patients experienced vision loss of 0.3 logarithm of the minimum angle of resolution units or greater. CONCLUSION: subfoveal fibrosis may develop or progress in neovascular age-related macular degeneration despite the absence of significant subfoveal hemorrhage and treatment with anti-VEGF. Development of anti-fibrotic therapeutics may be beneficial in reducing the incidence of subretinal fibrosis.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: